Literature DB >> 29154964

Lipotoxicity and the gut-liver axis in NASH pathogenesis.

Fabio Marra1, Gianluca Svegliati-Baroni2.   

Abstract

The pathogenesis of non-alcoholic fatty liver disease, particularly the mechanisms whereby a minority of patients develop a more severe phenotype characterised by hepatocellular damage, inflammation, and fibrosis is still incompletely understood. Herein, we discuss two pivotal aspects of the pathogenesis of NASH. We first analyse the initial mechanisms responsible for hepatocellular damage and inflammation, which derive from the toxic effects of excess lipids. Accumulating data indicate that the total amount of triglycerides stored in hepatocytes is not the major determinant of lipotoxicity, and that specific lipid classes act as damaging agents on liver cells. In particular, the role of free fatty acids such as palmitic acid, cholesterol, lysophosphatidylcholine and ceramides has recently emerged. These lipotoxic agents affect the cell behaviour via multiple mechanisms, including activation of signalling cascades and death receptors, endoplasmic reticulum stress, modification of mitochondrial function, and oxidative stress. In the second part of this review, the cellular and molecular players involved in the cross-talk between the gut and the liver are considered. These include modifications to the microbiota, which provide signals through the intestine and bacterial products, as well as hormones produced in the bowel that affect metabolism at different levels including the liver. Finally, the activation of nuclear receptors by bile acids is analysed.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Apoptosis; Ceramides; FXR; Fibroblast growth factor; Fibrosis; Free fatty acids; Inflammasome; Inflammation; JNK; Microbiota

Mesh:

Year:  2017        PMID: 29154964     DOI: 10.1016/j.jhep.2017.11.014

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  181 in total

1.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

2.  Palmitic Acid-Enriched Diet Induces Hepatic Steatosis and Injury in Adult Zebrafish.

Authors:  Ki-Hoon Park; Zhi-Wei Ye; Jie Zhang; Seok-Hyung Kim
Journal:  Zebrafish       Date:  2019-07-29       Impact factor: 1.985

3.  Sex-specific maternal calcium requirements for the prevention of nonalcoholic fatty liver disease by altering the intestinal microbiota and lipid metabolism in the high-fat-diet-fed offspring mice.

Authors:  Ping Li; Kesong Yan; Xuelian Chang; Xiaoyu Chen; Rui Wang; Xiuqin Fan; Tiantian Tang; Dawei Zhan; Kemin Qi
Journal:  Gut Microbes       Date:  2020-06-24

Review 4.  The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease.

Authors:  Myeong Jun Song; Harmeet Malhi
Journal:  Pharmacol Ther       Date:  2019-08-13       Impact factor: 12.310

5.  The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu.

Authors:  Hans Dieter Nischalke; Philipp Lutz; Eva Bartok; Benjamin Krämer; Bettina Langhans; Regina Frizler; Thomas Berg; Jochen Hampe; Stephan Buch; Christian Datz; Felix Stickel; Gunther Hartmann; Christian P Strassburg; Jacob Nattermann; Ulrich Spengler
Journal:  J Mol Med (Berl)       Date:  2019-10-21       Impact factor: 4.599

6.  Increased butyrate priming in the gut stalls microbiome associated-gastrointestinal inflammation and hepatic metabolic reprogramming in a mouse model of Gulf War Illness.

Authors:  Ratanesh Kumar Seth; Diana Kimono; Firas Alhasson; Sutapa Sarkar; Muayad Albadrani; Stephen K Lasley; Ronnie Horner; Patricia Janulewicz; Mitzi Nagarkatti; Prakash Nagarkatti; Kimberly Sullivan; Saurabh Chatterjee
Journal:  Toxicol Appl Pharmacol       Date:  2018-05-09       Impact factor: 4.219

7.  Green tea catechins in combination with irinotecan attenuates tumorigenesis and treatment-associated toxicity in an inflammation-associated colon cancer mice model.

Authors:  Gaurab Borah; Manuj Kumar Bharali
Journal:  J Egypt Natl Canc Inst       Date:  2021-07-26

8.  Screening of non-alcoholic steatohepatitis (NASH)-related datasets and identification of NASH-related genes.

Authors:  Ming-Jiang Liu; Hu Jin; Yu-Bing Chen; Jing-Jing Yu; Zhen-Ya Guo; Song-Qing He; Yong-Lian Zeng
Journal:  Int J Clin Exp Pathol       Date:  2021-05-15

Review 9.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

10.  Circulating microbiota-derived metabolites: a "liquid biopsy?

Authors:  Gemma Aragonès; Marina Colom-Pellicer; Carmen Aguilar; Esther Guiu-Jurado; Salomé Martínez; Fàtima Sabench; José Antonio Porras; David Riesco; Daniel Del Castillo; Cristóbal Richart; Teresa Auguet
Journal:  Int J Obes (Lond)       Date:  2019-08-06       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.